About EuroTEST

The initiative, originally named HIV in Europe, began in 2007 as way to bring attention to the importance of earlier diagnosis and care for people living with HIV. Although the initiative started with a HIV focus, the growing evidence has shown that HIV, hepatitis B and hepatitis C share overlaps in the modes of transmission and affect common key populations therefore, the initiative made a concerted effort in 2013 to also prioritise hepatitis. Since its initiation, HIV in Europe has built a European platform where independent experts from civil society, policy institutions, health care and European public health institutions to work toward influencing policy, knowledge sharing and building the evidence-base to support earlier diagnosis and care of HIV and viral hepatitis across Europe.

EuroTEST is not an organisation, but an initiative formed to inform processes, share knowledge and improve the evidence base around important issues of earlier testing and care. It is unique in its collaboration between stakeholders at a clinical, advocacy and public health level. EuroTEST is governed by an independent steering committee. The Coordinating Centre is at CHIP, RegionH, Copenhagen, and the political secretariat at the EATG. The conditions of funding the initiative are approved by the Steering Committee. 

Financial support of the HIV in Europe initiative provided by: Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Danish National Research Foundation (grant 126), European Commission under the 3rd  and 2nd Health Programmes,  European Centre for Disease Prevention and Control (ECDC), Gilead Sciences, GlaxoSmithKline, Merck, Pfizer, Schering-Plough, Swedish Research Council, ViiV Healthcare and Tibotec.

For more information about EuroTEST visit www.eurotest.org